With expanding waistlines, the prevalence of NAFLD has burgeoned to become the leading cause of chronic liver disease in the USA. A subset of patients with NAFLD meet criteria for NASH with its inherent risk of progression to cirrhosis. Verma et al. addressed the utility of alanine aminotransferase levels for predicting NASH or advanced fibrosis to decide who would benefit from the definitive test of liver biopsy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/nrgastro.2013.138 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!